Perrigo (NYSE:PRGO) Updates FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.250-2.550 for the period, compared to the consensus EPS estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Perrigo Stock Up 2.8%

Shares of PRGO traded up $0.34 during midday trading on Friday, reaching $12.88. 650,604 shares of the company were exchanged, compared to its average volume of 3,207,276. Perrigo has a 1-year low of $9.23 and a 1-year high of $24.60. The stock has a 50-day moving average price of $10.58 and a 200-day moving average price of $11.53. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 1.31. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -1.03, a P/E/G ratio of 1.38 and a beta of 0.51.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Research analysts expect that Perrigo will post 2.4 earnings per share for the current year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be given a $0.29 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 annualized dividend and a yield of 9.0%. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PRGO shares. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Perrigo has a consensus rating of “Hold” and an average target price of $19.33.

Hedge Funds Weigh In On Perrigo

Several institutional investors and hedge funds have recently made changes to their positions in PRGO. Corient Private Wealth LLC bought a new stake in shares of Perrigo in the fourth quarter worth $283,000. T. Rowe Price Investment Management Inc. raised its holdings in Perrigo by 35.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock valued at $19,295,000 after acquiring an additional 363,501 shares in the last quarter. Invesco Ltd. boosted its stake in Perrigo by 134.2% during the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after acquiring an additional 2,602,724 shares during the last quarter. Vident Advisory LLC grew its holdings in Perrigo by 7.0% during the 4th quarter. Vident Advisory LLC now owns 51,098 shares of the company’s stock worth $711,000 after acquiring an additional 3,350 shares in the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in shares of Perrigo by 126.3% in the 4th quarter. First Citizens Bank & Trust Co. now owns 39,207 shares of the company’s stock worth $546,000 after purchasing an additional 21,884 shares during the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.